IMUNON's R&D Day Highlights Positive Ovarian Cancer Treatment Progress and Potential Landmark Breakthrough with IMNN-001

IMUNON is hosting an R&D Day to showcase clinical progress of its novel immunotherapy, Phase 3 trial, and significant potential for women with ovarian cancer. The event features presentations from ovarian cancer key opinion leaders, clinicians, statistical experts, and IMUNON executives. IMUNON's CEO, Stacy Lindborg, states that IMNN-001 represents a potential landmark breakthrough in treating newly diagnosed ovarian cancer, with data indicating a 13-month improvement in overall survival with a favorable benefit-risk profile.